TaiMed Biologics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, TaiMed Biologics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
TaiMed Biologics: 9 sponsored US clinical trials, 1 recruiting.
TaiMed Biologics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1-infection, with 1 trials.
Top-decile sponsor footprint
TaiMed Biologics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
NCT07215468
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
NCT05275998
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
NCT04027387
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection
NCT03913195
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
NCT03110549
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
NCT02707861
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
NCT02475629
Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers
NCT01292174
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
NCT00784147
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the TaiMed Biologics pipeline
1 recruiting of 9 indexed (11% open); 7 completed (78%).
Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: HIV-1-infection (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
TaiMed Biologics: open-pipeline peers nationwide
Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
TaiMed Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this TaiMed Biologics page
9 registered trials is a research-attention snapshot, not an endorsement of TaiMed Biologics or any single study.
- 1 of TaiMed Biologics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV-1-infection is the condition TaiMed Biologics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1-infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. TaiMed Biologics pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.